Wednesday - July 16, 2025
Zepbound outduels Wegovy in weight-loss clinical trial
May 14, 2025
ITHACA, New York, May 14 -- Cornell University posted the following news:

* * *

Zepbound outduels Wegovy in weight-loss clinical trial

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the injectable drugs.

In the 72-week trial - led by an investigator at Weill Cornell Medicine and NewYork-Presbyterian . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products